Physician profile
Fred Michael Schultz
NPI 1568402618
$5,785.51
in general payments reported to CMS, 2019-2025
15 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $883 · 2021: $1,232 · 2022: $697 · 2023: $1,163 · 2024: $581 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,575.39 | 2019-2025 | Farxiga, Tezspire, Saphnelo |
| Abbvie INC. | $1,249.08 | 2021-2024 | Vraylar, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $664.12 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $647.80 | 2019-2020 | |
| Amgen INC. | $454.66 | 2019-2023 | Repatha |
| Novo Nordisk INC | $326.03 | 2019-2022 | |
| Horizon Therapeutics Plc | $271.84 | 2019-2023 | Krystexxa |
| Gilead Sciences, INC. | $262.91 | 2021-2024 | Epclusa |
| Janssen Pharmaceuticals, INC | $101.08 | 2019 | |
| Amarin Pharma, INC. | $86.30 | 2019 | |
| Antares Pharma, INC. | $76.95 | 2023 | Xyosted, Tlando, Nocdurna |
| Therapeuticsmd, INC. | $19.75 | 2020 | |
| Corcept Therapeutics | $18.70 | 2020 | |
| Glaxosmithkline, LLC. | $16.14 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.